Skip to content

Minimum Oxytocin Dose for Cesarean During Labor: Adaptative Clinical Trial

Minimum Oxytocin Dose for Cesarean During Labor: Adaptative Clinical Trial

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02794779
Acronym
MODCL
Enrollment
64
Registered
2016-06-09
Start date
2016-07-31
Completion date
2017-12-31
Last updated
2017-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section During Labor

Keywords

cesarean section, labor, oxytocin

Brief summary

Introduction: postpartum hemorrage is a leading cause of death after cesarean sections in Brazil. Oxytocin is the main drug for both prophylaxis and threatment of postpartum hemorrage because uterine atony is the most prevalent cause. Both excessive and too low oxytocin doses threaten the life of women. Objective: to determine the minimum effective dose of oxytocin for cesareans during labor. Method: adaptative clinical trial using a modified up and down method of two sequential groups: rule of three and continuous infusion. Allocation in rule of three or continuous infusion will be random and masked for patients and anesthesiologists. The minimum effective dose will be the effective dose for 90% of success (ED90 for preventing uterine atony).

Interventions

DRUGOxytocin

Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.

Sponsors

Brasilia University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 130 Years
Healthy volunteers
No

Inclusion criteria

* Cesarean delivery during labor. * Spinal anesthesia

Exclusion criteria

* Change of anesthesia

Design outcomes

Primary

MeasureTime frameDescription
Oxytocin dose10 minutesMinumum oxytocin dose for preventing uterine atony in 90% of cesareans.

Countries

Brazil

Contacts

Primary ContactGabriel MN Guimaraes, MD, MSc
gabrielmng@gmail.com+5561996455997
Backup ContactHelga BG Silva, MD, PhD
helgabgs@gmail.com5561991755997

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026